ProtoKinetix (ProtoKinetix) ROCE % : -102.52% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ProtoKinetix's annualized ROCE % for the quarter that ended in Dec. 2023 was -102.52%.

ProtoKinetix ROCE % Historical Data

The historical data trend for ProtoKinetix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix ROCE % Chart

ProtoKinetix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-1,041.69

-1,553.66

-599.49

-492.76

-96.85

ProtoKinetix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-586.93	-105.03	-109.43	-71.75	-102.52

ProtoKinetix ROCE % Calculation

ProtoKinetix's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.415	/	( ( (0.463 - 0.042)	+	(0.481 - 0.045) )	/ 2 )
	=	-0.415	/	( (0.421	+	0.436)	/ 2 )
	=	-0.415	/	0.4285
	=	-96.85 %

ProtoKinetix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-0.448	/	( ( (0.451 - 0.013)	+	(0.481 - 0.045) )	/ 2 )
	=	-0.448	/	( ( 0.438	+	0.436 )	/ 2 )
	=	-0.448	/	0.437
	=	-102.52 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

ProtoKinetix (OTCPK:PKTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ProtoKinetix ROCE % Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProtoKinetix (ProtoKinetix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

412 Mulberry Street, Marietta, OH, USA, 45750

Website

http://www.protokinetix.com

ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.

Executives

Clarence Edward Smith	director, 10 percent owner, officer: President & CEO	1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta	officer: CFO	412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young	10 percent owner	6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough	director	1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward	officer: CFO	705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen	director	4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory	director	2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior	director, officer: CEO	PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum	director, officer: President	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix (ProtoKinetix) Headlines

From GuruFocus

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research • 05-26-2023

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research GuruFocus Editor • 05-25-2023